Actinium Pharmaceuticals, Inc. ATNM
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is an oncology drug developer. Its lead program, Iomab-ACT, is in Phase 1 for CD45-targeted conditioning before CAR-T / cell and gene therapy (R/R NHL, B-cell malignancies, sickle cell disease BMT). Its next catalyst on record is Iomab-ACT: Data from ongoing clinical studies (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Iomab-ACT — Data from ongoing clinical studies (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Iomab-B | Conditioning for bone marrow transplant in R/R AML | radiopharmaceutical | Phase 3 |
| Iomab-ACT | Conditioning for CAR-T (R/R NHL, B-cell malignancies) and sickle cell disease BMT | radiopharmaceutical | Phase 1 |
| Actimab-A (AML/MDS) | R/R AML and high-risk MDS backbone therapy (with CLAG-M, NCI CRADA studies) | radiopharmaceutical | Phase 1 |
| Actimab-A (MDSC, solid tumors) | Solid tumors (HNSCC, NSCLC, GBM, MSI-high CRC) with checkpoint inhibitors | radiopharmaceutical | Phase 1 |
| ATNM-400 | Pan-tumor: mCRPC, NSCLC, breast cancer | radiopharmaceutical | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.